Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on February 24, 2009. The report details the entry into a material definitive agreement and unregistered sales of equity securities involving a $3 million investment deal with VetCure Inc. (now Vetericyn, Inc.) and its affiliates.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on specific events. However, it discloses the following capital transaction metrics:
- Total Investment: $3,000,000.
- Initial Payment: $1,000,000 paid on February 24, 2009.
- Remaining Payment: $2,000,000 due no later than August 1, 2009.
- Common Stock Issuance: 2,564,103 shares total, issued in tranches pro rata to payments.
- Series A Warrants: 1,500,000 shares at $1.87/share; 5-year term; exercisable after 6 months.
- Series B Warrants: 2,000,000 shares at $1.13/share; 3-year term; exercisable after 6 months.
- Series C Warrants: Up to 1,000,000 shares at $1.94/share; 5-year term; issued at a 2:1 ratio with Series B exercises.
Material Changes and Agreements
The filing reports the following material changes:
- Rescission of Prior Agreement: The Purchase Agreement dated January 26, 2009, was rescinded and replaced by the new agreement dated February 24, 2009.
- Revenue Sharing Amendment: The Distribution Agreement with VetCure was amended to reflect the name change to Vetericyn, Inc.
- Territory Expansion: The distribution territory was expanded from the United States to include Canada and Puerto Rico.
- Contract Modification: Section 4.6 ("Equity Compensation") was deleted from the Distribution Agreement.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- The company includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks described in their Form 10-K.
- The company does not intend to update forward-looking statements except as required by law.
- Regulatory Compliance: The securities were sold under Section 4(2) exemption, restricted to accredited investors with no public advertising or general solicitation.
Investor Verification Checklist
- Verify the exact number of shares issued upon the initial $1,000,000 payment versus the total 2,564,103 shares authorized.
- Confirm the status of the $2,000,000 remaining payment due by August 1, 2009.
- Review the full text of Exhibits 10.4 (Purchase Agreement) and 10.5 (Amendment) for specific covenants and conditions not summarized here.
- Check subsequent filings to confirm if the Series C warrants were issued based on Series B exercises.
- Verify the impact of the expanded territory (Canada/Puerto Rico) on future revenue projections.